Flagship Pioneering launched Cellarity, focused on studying and altering cell behaviors as a means of drug development.
Researchers at The Scripps Research Institute in Florida published a study in the journal Science describing a newly discovered biological system that manages how cells respond to exposure to opioids.
Researchers with the Hubrecht Institute in Utrecht, Netherlands and Radboud University in Nijmegen, Netherlands, developed a human model using organoids to evaluate the function of specific genes commonly mutated in liver cancer.
Vaunted immunotherapy pioneers from the Dana-Farber Cancer Institute won a key court case that could be worth billions of dollars.
An American astronaut experienced multiple biological changes in space but returned to normal – with some exceptions – after coming back to Earth, according to a study involving twin brothers that shed light on how space flight affects the human body.
Akoya Biosciences Inc., a Telegraph Hill Partners company, acquired PerkinElmer Inc.’s Phenoptics portfolio.
Denmark’s Novo Nordisk will cut around 250 jobs in the United States, but the drugmaker will also hire an as-yet undetermined number of staff to new positions.
In another example of companies focused on aging-related diseases, Elevian launched with $5.5 million in seed funding.
Cambridge, Mass.-based Twentyeight-Seven Therapeutics (28-7) completed a $65 million Series A financing.
Among the industry group PhRMA’s findings was that overall R&D spending was at an all-time high in 2017, hitting $71.4 billion, up from $65.5 billion in 2016 and from $29.8 billion in 2001.